“Many of the patients enrolled in the trial had either not undergone any testing or not completed the long-duration treatment… Most of the patients enrolled in the trial had extensive disease affecting both their lungs,” Dr. C Padmapriyadarsini, Director of the Chennai-based National Institute for Research in Tuberculosis and the trial coordinator of the modified BPaL regimen, told The Hindu. …
